IDEMIA
19.7.2021 11:28:07 CEST | Business Wire | Press release
IDEMIA Group announced today the appointment of Dominique Cerutti as Group Board Member, effective July 1st 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210719005297/en/
Dominique Cerutti comes with over 35 years of experience in Technology, R&D and Engineering services. He has held several CEO positions of leading technology companies and his expertise in growing large-scale international businesses will be a significant contribution to IDEMIA’s strategic vision.
“Dominique is a very seasoned leader with a demonstrated track record in transforming and growing large-scale international technology businesses. He will be instrumental for the Group moving forward”, said Pierre Barrial, IDEMIA Group President & CEO.
“We are pleased to welcome Dominique Cerutti to the IDEMIA Board. With more than 35 years of experience, Dominique is an undisputed expert in security and technology and a tremendous addition to IDEMIA’s Board” said Yann Delabrière, Chairman of the Board
“I couldn’t be more honored and thrilled to be joining IDEMIA, global leader in Augmented Identity, at an exciting time in its development. I look forward to offering strategic guidance and contributing to making the world a safer place”, said Dominique Cerutti.
NOTE TO EDITORS – Dominique Cerutti’s biography
Starting June 2015, Dominique Cerutti spent 5 years as Chief Executive Officer of the Altran group. He was also Chairman of the Altran Board from June 2015 to April 2020, until the acquisition of the company by Capgemini. Under his leadership, Altran has become the undisputed global leader in Engineering and R&D services, growing from 20,000 to more than 50,000 engineers worldwide, with revenues up to 3.2bn euros. He has deeply transformed the company by adapting the organization, promoting new business models and driving major acquisitions, enabling Altran to stay ahead of the competition, drive the market and reshape the global ER&D industry. Fervent advocate of the acquisition by Capgemini, he has worked hand in hand with the Group to make the integration a success and stepped down at the end of 2020.
Before joining Altran, Dominique Cerutti was CEO and Chairman of the Managing Board of Euronext, the leading pan-European exchange. He established Euronext as an independent company and the leading pan-European Exchange, through a successful IPO following the acquisition of NYSE-Euronext by the ICE Group in November 2013 and the subsequent demerger of Euronext from NYSE. He led the strategic repositioning of Euronext as the premier pan-European financing center. He and his team have been deeply involved with the correction of the previously biased EU financial markets regulation, promoting transparency and increased investors protections within the EU financial markets.
He was previously President and Deputy CEO, and a board member of New-York Stock Exchange (NYSE), the world’s leading exchange Group.
Dominique Cerutti also spent over 20 years at IBM in an international career, where he contributed to the company’s strategic transformation. In particular, he served as Chief Executive Officer of IBM Global Services for the Europe, Middle East, Africa, and later for IBM Europe, after being Executive Assistant to Lou Gerstner, Chairman and CEO of IBM.
He held various Board positions at LCH-Clearnet, Euromed Business School, New-York Stock Exchange, Altran, Euronext, Genes’ink.
Since March 2021, he is chairman of Adarma’s Board, one of the largest independent security services companies in the UK.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
